<DOC>
	<DOCNO>NCT02141828</DOCNO>
	<brief_summary>A subset patient acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) harbor rearrangement MLL gene , detect either cytogenetic fluorescent situ hybridization evaluation time diagnosis . A protein call DOT1L play important role malignant process leukemia . EPZ-5676 molecule block activity DOT1L , therefore evaluate treatment patient MLL-rearranged leukemia .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Expanded Cohort Study EPZ-5676 Treatment Pediatric Patients With Relapsed/Refractory Leukemias Bearing Rearrangement MLL Gene</brief_title>
	<detailed_description>This Phase 1b study EPZ-5676 pediatric patient . The study two phase . The first phase ass escalate dos EPZ-5676 order determine maximally tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) EPZ-5676 28-day continuous IV infusion . Once MTD and/or RP2D establish , second phase study evaluate safety EPZ-5676 assess anti-leukemia activity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Age : &gt; 3 month &lt; 18 year age . 2 . Diagnosis : Patients must document relapsed/refractory ALL , AML , acute leukemia ambiguous lineage meet follow criterion : Patients must least received appropriate induction therapy regimen . Patients persistent leukemia induction therapy , recurrence leukemia time course treatment ( include allogeneic HSCT ) eligible ; Patients must &gt; 10 % leukemic blast bone marrow ; Patients must rearrangement involve MLL gene , include reciprocal chromosomal translocation involve 11q23 FISH , cytogenetic analysis , polymerase chain reaction ( PCR ) nextgeneration sequence ( NGS ) OR partial tandem duplication ( PTD ) MLL PCR NGS . 3 . Therapeutic Options : Patients must ineligible inappropriate treatment regimen know curative potential . 4 . Performance Level : Karnofsky &gt; 50 % pt &gt; 12 year ; Lansky &gt; 50 % pt &lt; 12 year age . 5 . Prior Therapy : Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Myelosuppressive Chemotherapy : 14 day must elapse since completion cytotoxic therapy Patients may receive hydroxyurea , lowdose cytarabine and/or glucocorticoid control peripheral blood leukemic cell count study entry At least 7 day since completion therapy hematopoietic growth factor At least 7 day since completion therapy biologic agent At least 21 day since receipt chimeric antigen receptor therapy modify T cell therapy At least 60 day prior total body irradiation ( TBI ) At least 60 day must elapse hematopoietic stem cell transplantation ( HSCT ) 6 . Renal Hepatic Function : Patient must adequate renal hepatic function indicate follow laboratory value : Patient must calculate creatinine clearance radioisotope GFR &gt; 60mL/min/1.73m2 normal serum creatinine base age/gender Total bilirubin &lt; 1.5 x ULN age normal conjugate bilirubin ALT AST &lt; 3 x ULN ( unless attribute leukemic involvement ) 7 . Cardiac Function : Patient must shorten fraction ( SF ) &gt; 27 % ejection fraction ( EF ) &gt; 50 % echocardiogram MUGA scan . 1 . Patients CNS 3 disease symptomatic CNS disease 2 . Clinically active heart disease include prolonged QTc prolong PR interval , history arrhythmias 3 . On immunosuppressive antileukemic therapy , exclude patient receive glucocorticoids management circulate blast count patient stable dose ( &lt; 20mg/m2/day prednisone equivalent ) systemic topical glucocorticoid therapy â‰¤ Grade 1 GvHD taper dose calcineurin inhibitor 4 . Patients know bleed diathesis prothrombin time ( PT ) aPTT &gt; 1.5 x ULN fibrinogen &lt; 0.5 x LLN 5 . Receiving prophylactic use hematopoietic colony stimulate factor 6 . Known history infection human immunodeficiency virus ( HIV ) chronic infection hepatitis B virus ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) 7 . Being actively treat another concurrent malignancy 8 . Pregnant nursing female ; 9 . Male patient willing use condom 10 . Uncontrolled intercurrent illness include , limited uncontrolled infection , significant graftversushostdisease ( GvHD ) ( Grade 24 ) , psychiatric illness/social situation would limit compliance study requirement 11 . Patients concurrently receive strong inducers/inhibitors CYP3A 12 . Patients known history Trisomy 21 ( Down Syndrome ) , history congenital immunodeficiency inherit marrow failure disorder . 13 . Patients know bleeding diathesis , PT ( Prothrombin time ) aPTT ( activate partial thromboplastin time ) &gt; 1.5x ULN &lt; 0.5x LLN .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Advanced hematologic malignancy</keyword>
	<keyword>Epizyme</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>MLL gene</keyword>
	<keyword>11q23</keyword>
	<keyword>Ambiguous lineage</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>Acute leukemia</keyword>
	<keyword>MLL-r</keyword>
</DOC>